Protalix Biotherapeutics

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Protalix BioTherapeutics excels in Q2 with milestone achievements and revenue growth

Protalix BioTherapeutics delivered strong financial performance in Q2 2023, driven by milestone achievements and revenue growth.
The company's robust balance sheet, successful product launches, and focus on innovation position it well for future success.
While facing challenges in a competitive market, Protalix has opportunities to expand market presence, drive innovation, and enhance shareholder value.
Strategic execution and continued focus on profitability will be key for Protalix to capitalize on opportunities and navigate industry challenges.

Protalix BioTherapeutics navigates mixed Q3 results, eyes pipeline advancements

Protalix BioTherapeutics reported a mixed financial performance in Q3 2023, with revenue fluctuations and cost management efforts impacting the bottom line. The company remains focused on advancing its pipeline candidates and commercial launches to drive future growth and market success.
Despite challenges in revenue streams and cost structures, Protalix demonstrated operational stability and strategic decision-making in navigating market dynamics. The company's strong leadership team, diverse product portfolio, and ongoing clinical programs position it well for future opportunities and growth.
Overall, Protalix BioTherapeutics showcased resilience amidst external events, with a strategic focus on product approvals, cost optimization, and clinical advancements. The company's financial stability, strong cash reserves, and commitment to innovation underscore its competitive position in the biopharmaceutical industry.

Protalix BioTherapeutics reports stellar Q4 performance and growth opportunities

Protalix BioTherapeutics delivered strong financial results in Q4 2023, driven by the successful launch of Elfabrio and cost-saving measures.
Strategic leadership additions and a robust cash position position the company well for future growth and innovation.
While challenges persist in sustaining growth and managing costs, opportunities in new drug development and market expansion offer promising avenues for Protalix.

Protalix BioTherapeutics reports Q1 progress with promising pipeline advancements

Protalix BioTherapeutics navigated revenue challenges with cost management and maintained financial stability through a strong cash position.
Progress in the pipeline with PRX-115's positive Phase I results and upcoming Phase II trial signals potential growth opportunities.
Analyst inquiries underscore the importance of addressing safety concerns, conducting robust trials, and effectively positioning products in a competitive market.

Protalix BioTherapeutics advances PRX-115 for uncontrolled gout treatment

Protalix BioTherapeutics showcased promising results for PRX-115 in uncontrolled gout, with plans for Phase II trial and a focus on renal rare diseases.
Despite a net loss in Q2 2024, the company's strong cash position supports operations and strategic R&D efforts for future growth.
Challenges in financial performance call for cost management strategies, while opportunities lie in clinical advancements and innovative product development.

Protalix BioTherapeutics reports robust Q3 earnings and advances innovative therapies

Protalix BioTherapeutics delivered strong financial performance in Q3 2024, marked by revenue growth, net income, and debt-free status, showcasing operational efficiency.
PRX-115's positive Phase I trial results and upcoming Phase II trial highlight Protalix's commitment to innovation and advancing novel therapies for unmet medical needs.
While facing challenges in regulatory dynamics and competitive landscape, Protalix has opportunities to leverage its strengths in product development and market expansion for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARMIEL, Israel, Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock

Protalix BioTherapeutics Inc (NYSE: PLX) has announced an exclusive worldwide license agreement with SarcoMed USA Inc for alidornase alfa, also known as PRX–110, for use in the treatment of any human respiratory disease or condition including, sarcoidosis, pulmonary fibrosis, and other related disorders via inhaled delivery. Alidornase alfa is the Company's proprietary chemically-modified plant cell-expressed recombinant form of human deoxyribonuclease I (DNase I), administered through inhalation.

Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions

CARMIEL, Israel, Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

CARMIEL, Israel, and BOSTON, Feb. 10, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

CARMIEL, Israel, Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

CARMIEL, Israel, Jan. 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January

CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics Issues 2020 Letter to Shareholders

CARMIEL, Israel and BOSTON, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix had a PDUFA date for Fabry Disease drug PRX-102 on January 27, now postponed to April 27. The postponement seems only procedural and strictly Covid related, as the accelerated approval timeline was not affected, nor did the FDA request any new data.

FDA Decision For Protalix Postponed Due To Covid, But Fundamentals Remain Strong

CARMIEL, Israel, Nov. 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

CARMIEL, Israel, Nov. 5, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based...

Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2020 Results - Earnings Call Transcript

CARMIEL, Israel, Oct. 29, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

CARMIEL, Israel, Oct. 26, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant...

Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable

BOSTON and CARMIEL, Israel, Oct. 2, 2020 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), and Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Could Claim Substantial Global Market Share In Fabry Disease

CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards

Protalix shares have gone nowhere since June.

Now Armed With A PDUFA Date, Protalix Is Even More Undervalued

CARMIEL, Israel,, Aug. 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease

CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review

Protalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q2 2020 Results - Earnings Call Transcript

CARMIEL, Israel, Aug. 6, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020

CARMIEL, Israel, Aug. 3, 2020 /PRNewswire/Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020

CARMIEL, Israel, July 23, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant.

Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases

News for Protalix Biotherapeutics Stock (PLX)